BRPI0510570A - composição de vacina - Google Patents
composição de vacinaInfo
- Publication number
- BRPI0510570A BRPI0510570A BRPI0510570-6A BRPI0510570A BRPI0510570A BR PI0510570 A BRPI0510570 A BR PI0510570A BR PI0510570 A BRPI0510570 A BR PI0510570A BR PI0510570 A BRPI0510570 A BR PI0510570A
- Authority
- BR
- Brazil
- Prior art keywords
- vaccine composition
- antigen
- vaccine
- eso
- saponin
- Prior art date
Links
- 229960005486 vaccine Drugs 0.000 title abstract 4
- 239000000203 mixture Substances 0.000 title abstract 3
- 239000000427 antigen Substances 0.000 abstract 2
- 102000036639 antigens Human genes 0.000 abstract 2
- 108091007433 antigens Proteins 0.000 abstract 2
- 102100025570 Cancer/testis antigen 1 Human genes 0.000 abstract 1
- 101000856237 Homo sapiens Cancer/testis antigen 1 Proteins 0.000 abstract 1
- 101001005719 Homo sapiens Melanoma-associated antigen 3 Proteins 0.000 abstract 1
- 102100025082 Melanoma-associated antigen 3 Human genes 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 108091034117 Oligonucleotide Proteins 0.000 abstract 1
- 239000002671 adjuvant Substances 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 238000009472 formulation Methods 0.000 abstract 1
- 230000003308 immunostimulating effect Effects 0.000 abstract 1
- 239000001397 quillaja saponaria molina bark Substances 0.000 abstract 1
- 229930182490 saponin Natural products 0.000 abstract 1
- 150000007949 saponins Chemical class 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001184—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
- A61K39/001186—MAGE
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001184—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
- A61K39/001188—NY-ESO
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Mycology (AREA)
- Oncology (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Immunology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
Abstract
COMPOSIçãO DE VACINA. A presente invenção fornece novas formulações de vacina para o tratamento de antígenos do câncer. A vacina compreende um antígeno MAGE-3 modificado, um antígeno NY-ESO- 1, e um adjuvante compreendendo uma saponina e um oligonucleotídeo imunoestimulador.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB0409940.4A GB0409940D0 (en) | 2004-05-04 | 2004-05-04 | Vaccine |
PCT/EP2005/004956 WO2005105139A2 (en) | 2004-05-04 | 2005-05-02 | Mage-3 and ny-eso-1 based polyvalent vaccine for cancer immunotherapy |
Publications (1)
Publication Number | Publication Date |
---|---|
BRPI0510570A true BRPI0510570A (pt) | 2007-11-20 |
Family
ID=32482653
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BRPI0510570-6A BRPI0510570A (pt) | 2004-05-04 | 2005-05-02 | composição de vacina |
Country Status (16)
Country | Link |
---|---|
US (1) | US20070243196A1 (pt) |
EP (1) | EP1755657A2 (pt) |
JP (1) | JP2007536326A (pt) |
CN (1) | CN1980691A (pt) |
AU (1) | AU2005237256A1 (pt) |
BR (1) | BRPI0510570A (pt) |
CA (1) | CA2564470A1 (pt) |
GB (1) | GB0409940D0 (pt) |
IL (1) | IL178681A0 (pt) |
MA (1) | MA28639B1 (pt) |
MX (1) | MXPA06012723A (pt) |
NO (1) | NO20065480L (pt) |
NZ (1) | NZ550967A (pt) |
RU (1) | RU2006138283A (pt) |
WO (1) | WO2005105139A2 (pt) |
ZA (1) | ZA200608693B (pt) |
Families Citing this family (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2007137986A2 (en) * | 2006-05-26 | 2007-12-06 | Glaxosmithkline Biologicals Sa | Vaccination against cancer |
GB0612342D0 (en) * | 2006-06-21 | 2006-08-02 | Glaxosmithkline Biolog Sa | Method |
PL2118128T3 (pl) * | 2007-01-15 | 2013-03-29 | Glaxosmithkline Biologicals Sa | Białka fuzyjne zawierające antygeny odrzucenia nowotworu NY-ESO-1 i LAGE-1 |
WO2008110372A1 (en) | 2007-03-13 | 2008-09-18 | University Of Zurich | Monoclonal human tumor-specific antibody |
PT2148697E (pt) | 2007-05-24 | 2012-12-24 | Glaxosmithkline Biolog Sa | Composição liofilizada de wt-1 contendo cpg |
WO2009127666A2 (en) * | 2008-04-15 | 2009-10-22 | Glaxosmithkline Biologicals S.A. | Method and compositions |
CN101381402B (zh) * | 2008-10-20 | 2011-06-01 | 中国人民解放军第三军医大学 | Ny-eso-1肿瘤抗原模拟表位及其应用 |
EP2408933A2 (en) | 2009-03-17 | 2012-01-25 | MDxHealth SA | Improved detection of gene expression |
GB0910046D0 (en) | 2009-06-10 | 2009-07-22 | Glaxosmithkline Biolog Sa | Novel compositions |
DK2663580T3 (en) * | 2011-01-10 | 2017-03-13 | Ct Atlantic Ltd | COMBINATION THERAPY INCLUDING TUMOR ASSOCIATED ANTI-BINDING ANTIBODIES |
GB201116248D0 (en) | 2011-09-20 | 2011-11-02 | Glaxosmithkline Biolog Sa | Liposome production using isopropanol |
CA3027289A1 (en) * | 2013-05-14 | 2014-11-20 | Zoetis Services Llc | Vaccine compositions comprising sp oil and p-class immunostimulatory oligonucleotides |
AU2014292926B2 (en) | 2013-07-25 | 2020-03-05 | Exicure Operating Company | Spherical nucleic acid-based constructs as immunostimulatory agents for prophylactic and therapeutic use |
JP6581604B2 (ja) | 2014-06-04 | 2019-09-25 | イグジキュア, インコーポレーテッドExicure, Inc. | 予防的または治療的適用のためのリポソーム球状核酸による免疫調節物質の多価送達 |
GB201413665D0 (en) | 2014-07-03 | 2014-09-17 | Transimmune Ag And Yale University | Method for obtaining globally activated monocytes |
WO2016019298A2 (en) * | 2014-08-01 | 2016-02-04 | Texas Tech University System | Cancer testis antigen sperm protein 17 as a target for breast cancer immunotherapy and diagnosis |
CA2968531A1 (en) | 2014-11-21 | 2016-05-26 | Northwestern University | The sequence-specific cellular uptake of spherical nucleic acid nanoparticle conjugates |
US11364304B2 (en) | 2016-08-25 | 2022-06-21 | Northwestern University | Crosslinked micellar spherical nucleic acids |
US11696954B2 (en) | 2017-04-28 | 2023-07-11 | Exicure Operating Company | Synthesis of spherical nucleic acids using lipophilic moieties |
WO2018226931A1 (en) * | 2017-06-07 | 2018-12-13 | David Weiner | Mage-a vaccines and methods of treatment using the same |
WO2019061297A1 (zh) * | 2017-09-29 | 2019-04-04 | 苏州工业园区唯可达生物科技有限公司 | 一种cd4辅助性t细胞表位融合肽及其疫苗 |
GB201804468D0 (en) * | 2018-03-21 | 2018-05-02 | Valo Therapeutics Oy | PeptiCRAd Cancer Therapy |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5057540A (en) * | 1987-05-29 | 1991-10-15 | Cambridge Biotech Corporation | Saponin adjuvant |
US5278302A (en) * | 1988-05-26 | 1994-01-11 | University Patents, Inc. | Polynucleotide phosphorodithioates |
US4912094B1 (en) * | 1988-06-29 | 1994-02-15 | Ribi Immunochem Research Inc. | Modified lipopolysaccharides and process of preparation |
FR2649012B1 (fr) * | 1989-07-03 | 1991-10-25 | Seppic Sa | Emulsions multiphasiques injectables |
FR2649013B1 (fr) * | 1989-07-03 | 1991-10-25 | Seppic Sa | Vaccins et vecteurs de principes actifs fluides contenant une huile metabolisable |
AU725615B2 (en) * | 1996-02-23 | 2000-10-12 | British Telecommunications Public Limited Company | Optical interconnect |
DE69943359D1 (de) * | 1998-02-05 | 2011-05-26 | Glaxosmithkline Biolog Sa | Tumorassoziierte Antigenderivate der Mage-Familie, zur Herstellung von Fusionsproteinen mit T-Helper Epitope und Zusammensetzungen zur Impfung |
US6686147B1 (en) * | 1998-07-15 | 2004-02-03 | Ludwig Institute For Cancer Research | Cancer associated antigens and uses therefor |
US20030044813A1 (en) * | 2001-03-30 | 2003-03-06 | Old Lloyd J. | Cancer-testis antigens |
-
2004
- 2004-05-04 GB GBGB0409940.4A patent/GB0409940D0/en not_active Ceased
-
2005
- 2005-05-02 CN CNA2005800137978A patent/CN1980691A/zh active Pending
- 2005-05-02 WO PCT/EP2005/004956 patent/WO2005105139A2/en active Application Filing
- 2005-05-02 BR BRPI0510570-6A patent/BRPI0510570A/pt not_active IP Right Cessation
- 2005-05-02 NZ NZ550967A patent/NZ550967A/en unknown
- 2005-05-02 CA CA002564470A patent/CA2564470A1/en not_active Abandoned
- 2005-05-02 JP JP2007512044A patent/JP2007536326A/ja active Pending
- 2005-05-02 RU RU2006138283/15A patent/RU2006138283A/ru not_active Application Discontinuation
- 2005-05-02 MX MXPA06012723A patent/MXPA06012723A/es not_active Application Discontinuation
- 2005-05-02 AU AU2005237256A patent/AU2005237256A1/en not_active Abandoned
- 2005-05-02 EP EP05741937A patent/EP1755657A2/en not_active Withdrawn
- 2005-05-02 US US11/568,566 patent/US20070243196A1/en not_active Abandoned
-
2006
- 2006-10-17 IL IL178681A patent/IL178681A0/en unknown
- 2006-10-18 ZA ZA200608693A patent/ZA200608693B/xx unknown
- 2006-11-28 NO NO20065480A patent/NO20065480L/no not_active Application Discontinuation
- 2006-11-28 MA MA29494A patent/MA28639B1/fr unknown
Also Published As
Publication number | Publication date |
---|---|
JP2007536326A (ja) | 2007-12-13 |
NZ550967A (en) | 2009-01-31 |
MXPA06012723A (es) | 2007-02-14 |
IL178681A0 (en) | 2007-02-11 |
AU2005237256A1 (en) | 2005-11-10 |
ZA200608693B (en) | 2010-01-27 |
CN1980691A (zh) | 2007-06-13 |
CA2564470A1 (en) | 2005-11-10 |
NO20065480L (no) | 2006-11-28 |
EP1755657A2 (en) | 2007-02-28 |
RU2006138283A (ru) | 2008-06-10 |
MA28639B1 (fr) | 2007-06-01 |
WO2005105139A2 (en) | 2005-11-10 |
US20070243196A1 (en) | 2007-10-18 |
GB0409940D0 (en) | 2004-06-09 |
WO2005105139A3 (en) | 2006-04-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BRPI0510570A (pt) | composição de vacina | |
CY1121211T1 (el) | Εμβολιο ιου ερπητα ζωστηρα | |
CY1116904T1 (el) | Εμβολιο | |
MX2009003325A (es) | Vacuna que comprende un adyuvante de emulsion de aceite en agua. | |
TW200700079A (en) | Composition | |
BR0114786A (pt) | Composição imunogênica, método de tratamento de um paciente que sofre de, ou que é suscetìvel a, um câncer, e, uso de uma combinação de uma saponina, um oligotìdeo imunoestimulador e um antìgeno de câncer, e, método para a manufatura de uma composição | |
PT1187629E (pt) | Composicao adjuvante que compreende saponina e um oligonucleotido imunoestimulador | |
PH12014501835A1 (en) | Novel adjuvant compositions | |
ATE491467T1 (de) | Impfstoffzusammensetzungen mit virosomen und einem saponin-adjuvans | |
BRPI0710508B8 (pt) | composição de pepticorpo terapêutico liofilizado estável, kit para preparar uma composição farmacêutica aquosa, e métodos para fabricar um pepticorpo terapêutico liofilizado e para preparar uma composição de pepticorpo terapêutico reconstituído | |
ATE426412T1 (de) | Adjuvante influenza-vakzine | |
WO2007120673A3 (en) | Immunogenic wt-1 peptides and methods of use thereof | |
CR10559A (es) | Vacuna de influenza | |
CO6551750A2 (es) | Vacuna del virus del dengue inactivado que incluye un adyuvante sin aluminio | |
CL2019002876A1 (es) | Síntesis de triterpeno-saponina, intermediarios y combinaciones adyuvantes. | |
BR112012013329A2 (pt) | composição oral e método para o tratamento de uma doença ou condição do tecido mole da cavidade oral | |
EA201001478A1 (ru) | Вакцина | |
GB2444676A (en) | Adjuvanted vaccine | |
BR112014020025A2 (pt) | vacinas de subunidade de rotavirus e métodos de produção e uso das mesmas | |
TW200637573A (en) | Peptide for delivery of mucosal vaccines | |
TNSN07187A1 (en) | Immunotherapeutic formulations to generate autoantibodies capable to avoid the binding of interleukin-2 to its receptor. their use in the treatment of cancer | |
WO2007120603A3 (en) | Immunogenic bcr-abl peptides and methods of use thereof | |
UY31510A1 (es) | Vacunacontra la malaria, especifica para el parasito plasmodium falciparum | |
BR112021017691A2 (pt) | Formulações imunogênicas para o tratamento do câncer | |
CY1113746T1 (el) | Εμβολιο που περιλαμβανει ανοσοενισχυτικο γαλακτωμα ελαιου σε υδωρ |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE AS 6A E 7A ANUIDADES. |
|
B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2158 DE 15/05/2012. |